|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administered_by
|
gptkb:healthcare_professionals
intravenous infusion
adults and children
high-risk patients
|
|
gptkbp:approves
|
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:associated_with
|
lower mortality rates
|
|
gptkbp:can_be_combined_with
|
supportive care
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
collaboration with other companies
|
|
gptkbp:developed_in_response_to
|
gptkb:COVID-19_pandemic
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lilly's COVID-19 antibody therapy
|
|
gptkbp:indication
|
mild to moderate COVID-19
|
|
gptkbp:involves
|
antibody infusion therapy
|
|
gptkbp:is_analyzed_in
|
peer-reviewed journals
|
|
gptkbp:is_available_in
|
gptkb:various_countries
|
|
gptkbp:is_based_on
|
gptkb:scientific_research
|
|
gptkbp:is_considered
|
a therapeutic option
a key treatment option
an investigational treatment
|
|
gptkbp:is_discussed_in
|
gptkb:literature
|
|
gptkbp:is_evaluated_by
|
safety and efficacy
real-world studies
|
|
gptkbp:is_monitored_by
|
infusion reactions
|
|
gptkbp:is_not_areplacement_for
|
vaccination
|
|
gptkbp:is_part_of
|
gptkb:Eli_Lilly's_COVID-19_portfolio
COVID-19 treatment guidelines
COVID-19 therapeutic landscape
emergency response to COVID-19
monoclonal antibody strategy
|
|
gptkbp:is_promoted_by
|
Eli Lilly marketing campaigns
|
|
gptkbp:is_recommended_by
|
health authorities
|
|
gptkbp:is_studied_in
|
clinical trials
|
|
gptkbp:is_subject_to
|
regulatory oversight
|
|
gptkbp:is_supported_by
|
clinical evidence
|
|
gptkbp:is_used_in
|
inpatient settings
outpatient settings
|
|
gptkbp:is_used_to
|
prevent disease progression
|
|
gptkbp:marketed_as
|
gptkb:Bamlanivimab
gptkb:Etesevimab
|
|
gptkbp:part_of
|
therapeutic monoclonal antibody treatments
|
|
gptkbp:received_emergency_use_authorization
|
gptkb:2020
|
|
gptkbp:reduces
|
risk of hospitalization
|
|
gptkbp:requires
|
prescription
|
|
gptkbp:shown_to_be_effective_in
|
reducing viral load
|
|
gptkbp:shown_to_reduce
|
symptoms duration
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
diarrhea
|
|
gptkbp:suitable_for
|
severe COVID-19 cases
|
|
gptkbp:targets
|
SARS-Co V-2 virus
|
|
gptkbp:uses
|
monoclonal antibodies
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly
|
|
gptkbp:bfsLayer
|
4
|